Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer

doi:10.4240/wjgs.v15.i5.906

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2935)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

106

WORD

HTML

1475

Figures (1-1)

258

Tables (1-5)

262

Sum=2136

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

142

Download

657

Sum=799

May 27, 2023 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. May 27, 2023; 15(5): 906-916
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906

Table 2 Comparison of short-term efficacy between the two groups, n (%)

Group	iCR	iPR	iSD	iPD	ORR	DCR
Control group (n = 43)	9 (20.93)	16 (37.21)	11 (25.58)	7 (16.28)	25 (58.14)	36 (83.72)
Observation group (n = 39)	20 (51.28)	12 (30.77)	6 (15.38)	1 (2.56)	32 (82.05)	38 (97.44)
χ²					5.518	4.369
P value					0.019	0.037

ORR: Objective response rate; DCR: Disease control rate; iCR: Immune complete response; iPR: Immune partial response; iSD: Immune stable disease; iPD: Immune progressive disease.

Citation: Jiang YL, Fu XY, Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15(5): 906-916
URL: https://www.wjgnet.com/1948-9366/full/v15/i5/906.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i5.906